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Heterozygous PMS2 germline mutations are associated with Lynch syndrome. Up to one third of these mutations are
genomic deletions. Their detection is complicated by a pseudogene (PMS2CL), which – owing to extensive interparalog
sequence exchange – closely resembles PMS2 downstream of exon 12. A recently redesigned multiplex ligation-dependent
probe ampliﬁcation (MLPA) assay identiﬁes PMS2 copy number alterations with improved reliability when used with refer-
ence DNAs containing equal numbers of PMS2- and PMS2CL-speciﬁc sequences. We selected eight such reference samples
– all publicly available – and used them with this assay to study 13 patients with PMS2-defective colorectal tumors. Three
presented deleterious alterations: an Alu-mediated exon deletion; a 125-kb deletion encompassing PMS2 and four addi-
tional genes (two with tumor-suppressing functions); and a novel deleterious hybrid PMS2 allele produced by recombination
with crossover between PMS2 and PMS2CL, with the breakpoint in intron 10 (the most 50 breakpoint of its kind reported
thus far). We discuss mechanisms that might generate this allele in different chromosomal conﬁgurations (and their
diagnostic implications) and describe an allele-speciﬁc PCR assay that facilitates its detection. Our data indicate that the
redesigned PMS2 MLPA assay is a valid ﬁrst-line option. In our series, it identiﬁed roughly a quarter of all PMS2 muta-
tions. VC 2012 Wiley Periodicals, Inc.
INTRODUCTION
Lynch syndrome (MIM#120435) is the most
common heritable cause of neoplastic disease in
the large intestine. Formerly referred to as hered-
itary nonpolyposis colorectal cancer, this syn-
drome accounts for approximately 2-3% of all
colorectal malignancies and is associated with an
increased risk for cancer at other sites as well
(Cunningham et al., 2001; Lynch and de la Chap-
elle, 2003; Hampel et al., 2008; Lynch et al.,
2009). It is caused mainly by heterozygous germ-
line mutations in the mismatch repair (MMR)
genes, in most cases MSH2 (40% of cases) or
MLH1 (50%) (Liu et al., 1996; Peltomaki,
2003). A third MMR gene, MSH6, has been
found mutated in 10% of cases (Berends et al.,
2002; Hendriks et al., 2004; Plaschke et al.,
2004). Another essential MMR gene, PMS2, was
previously thought to play only a minor role in
colorectal cancer predisposition. However, in a
large series of unselected colorectal carcinomas,
evidence of primary alteration of PMS2 (i.e., im-
munohistochemical ﬁndings of isolated loss of
PMS2 protein expression with normal expression
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of its heterodimeric partner MLH1 and of the
other MMR proteins) was approximately as com-
mon as loss of MSH2 (Truninger et al., 2005). In
this study and others (Clendenning et al., 2008;
Senter et al., 2008), heterozygous PMS2 muta-
tions displayed lower penetrance than mutations
involving other MMR genes, as reﬂected by later
onset of colorectal cancer (average: 59 years vs.
45 years in MLH1/MSH2 mutation carriers) and
weaker family histories of Lynch-syndrome asso-
ciated cancers. Consequently, patients with these
mutations were unlikely to meet the Amsterdam
II criteria (Vasen et al., 1999).
Mutational analysis of PMS2, which is located
on chromosome 7 (band p22), is complicated by
the existence of 15 PMS2 pseudogenes on the
same chromosome. One of these, a transcribed
pseudogene known as PMS2CL, lies on 7p22
itself, just 0.7 Mb centromeric to the functional
gene. PMS2CL is the result of the inverted dupli-
cation of a 100-kb repeat element that includes
the 30 region of PMS2 containing exons 9–15.
The pseudogene contains six of these PMS2
exons (9 and 11-15) but lacks exon 10 owing to
an Alu-mediated 2.7-kb deletion (De Vos et al.,
2004).
Recombination involving these two duplicons
has led to considerable sequence homogenization
at their centers and to a lesser extent at their
extremities (Hayward et al., 2007). Recombina-
tion with crossover and/or gene-conversion
between the paralogs situated at the inner ends
of the duplicons produces hybrid PMS2 alleles
that contain PMS2CL-derived sequences (as
deﬁned by NCBI RefSeq NC_000007.13) as well
as hybrid PMS2CL alleles with sequences derived
from PMS2 (according to RefSeq NM_000535.5).
The transfer involves mainly sequences lying
between intron 12 and the 30 ends of the two
paralogs – in terms of coding sequences, those of
exons 13–15 (Hayward et al., 2007; Ganster et al.,
2010; van der Klift et al., 2010). The PMS2CL
sequences of these exons are almost always syn-
onymous variants (with respect to those of the
functional gene). The only exception is a mis-
sense alteration (p.N775S) in PMS2CL exon 14.
However, hybrid PMS2 alleles containing this
variant represent 4–25% of all PMS2 alleles found
in the general population, depending on the eth-
nic group (Ganster et al., 2010). Therefore, the
vast majority of hybrid PMS2 alleles identiﬁed
thus far are classiﬁed as nondeleterious.
Because of the very high prevalence of hybrid
PMS2 and PMS2CL alleles (van der Klift et al.,
2010), the 30 regions of the gene and pseudogene
cannot be reliably distinguished on the basis of
sequence differences with respect to their respec-
tive NCBI RefSeqs. This is a serious limitation
for genomic DNA (gDNA)-based assays used for
PMS2 mutation analyses [e.g., exon sequencing
to detect point mutations and multiplex ligation-
dependent probe ampliﬁcation (MLPA) for the
identiﬁcation of deletions/ampliﬁcations].
The shortcomings of gDNA-based sequencing
of PMS2 exons 11-15 can be effectively circum-
vented with recently developed RNA-based strat-
egies, such as complementary DNA (cDNA)
sequencing (Etzler et al., 2008; van der Klift
et al., 2010), or with long-range PCR (Vaughn
et al., 2010). New solutions are also needed for
the detection of copy number changes, above all
deletions, which appear to account for up to 33%
of all PMS2 mutations (van der Klift et al., 2010;
Vaughn et al., 2010). The MLPA assay kit used
until recently for this purpose (the P008-A1
PMS2 MLPA kit, MRC Holland, Amsterdam,
The Netherlands) contained only PMS2-speciﬁc
probes for exons 13-15, and this led to both false-
negative and false-positive results for these exons
due to the presence of hybrid alleles in many
gDNA samples. To address these problems, the
PMS2 MLPA kit has recently been redesigned.
The new version (kit P008-B1) contains gene-
and pseudogene-speciﬁc probes for exons 11-15,
as well as nonspeciﬁc probes for exons 12-15,
which hybridize to gene and pseudogene sequen-
ces and thus detect a total of four DNA copies in
the genome. These modiﬁcations have substan-
tially improved the reliability of the assay, speciﬁ-
cally from exons 12/13 downwards (Vaughn et al.,
2011). Owing, however, to wide interindividual
variability in the distribution of PMS2 and
PMS2CL sequences downstream of exon 12, copy
number variations (CNVs) can be accurately
detected only when each run includes reference
DNA samples known to contain two gene-speciﬁc
copies and two pseudogene-speciﬁc copies of
exons 11-15 sequences.
This study illustrates the pivotal role played by
these reference DNA samples and describes eight
publicly available samples that can be used with
the new PMS2 MLPA kit. We used this approach
to identify the presence of PMS2 deletions in
germline DNA from 13 patients whose colorectal
tumors were suspected to be caused by PMS2-
related Lynch syndrome. In three cases, MLPA
yielded evidence of deleterious PMS2 alterations,
which were subsequently veriﬁed and further
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characterized with other methods. Two were
deletions (one of which encompassed the entire
PMS2 gene and at least two other genes with
tumor-suppressing functions); the third was an
alteration that has not been previously described:
a deleterious hybrid PMS2 allele produced by
recombination with crossover between PMS2 and
PMS2CL.
MATERIAL AND METHODS
Patient and Reference DNA Samples
This study included gDNA samples from 13
patients with colorectal tumors displaying isolated
PMS2 expression loss (Table 1). One (patient
TR13) was recruited in the Department of Gas-
troenterology of the Santa Chiara Hospital in
Trento, Italy. The other 12 were enrolled at
the Institute of Molecular Cancer Research, Uni-
versity of Zurich, Switzerland. All patients gave
written informed consent to molecular genetic
testing.
In the 10 cases in which family history was
available, the pedigree fulﬁlled the revised Am-
sterdam II criteria (Vasen et al., 1999) (n ¼ 2) or
one or more of the criteria contained in the re-
vised Bethesda Guidelines (Umar et al., 2004)
(n ¼ 8). In 11 of the 13 patients, MLPA was the
ﬁrst-line method of mutation analysis. The other
two (CH6 and CH7) had undergone gDNA
sequencing in a previous study (Truninger et al.,
2005), which was negative for point mutations in
PMS2. DNA remaining after the completion of
this study was used now for MLPA analysis.
To identify appropriate reference DNA sam-
ples that could be used by all laboratories for
PMS2 MLPA analysis, we obtained 24 DNA sam-
ples from Coriell Cell Repositories (Camden, NJ)
and analyzed them by MLPA. Results were com-
pared with those for DNA samples from ﬁve con-
trols whose genotypes had been determined in a
previous study (Ganster et al., 2010). Candidate
samples found to contain two PMS2-speciﬁc cop-
ies and two PMS2CL-speciﬁc copies of each
sequence bound by the probes for exons 11-15
were selected as reference samples for this study.
We also used 150 DNA samples from individu-
als with different ethnic backgrounds (Ganster
et al., 2010) as negative controls in the allele-spe-
ciﬁc PCR assay described below.
MLPA
The P008-B1 PMS2 MLPA kit (MRC-Holland)
was used according to the manufacturer’s instruc-
tions to detect single and multiple exon deletions
(as well as possible duplications) in the PMS2
gene. The redesigned assay includes 24 PMS2-
speciﬁc probes (exons 1-15), ﬁve PMS2CL-speciﬁc
probes (exons 11-15), and ﬁve nonspeciﬁc probes
(exons 12-15) that hybridize to both PMS2 and
PMS2CL. Before MLPA analysis, all gDNA sam-
ples were puriﬁed with the QIAamp DNA Micro
kit (Qiagen, Hilden, Germany), and a total of 50-
100 ng of gDNA was used per MLPA reaction.
Each MLPA run included ﬁve appropriate refer-
ence DNA samples (selected as described above;
Table 2). MLPA results were analyzed with the
TABLE 1. Patients with Colorectal Tumors
Patient code Age Sex Site Stagea Gradea MSI
Revised AC
and BG
CH1 35 M C T3N1M0 3 P BG1 and BG4
CH2 29 M A T3N0M0 2 Na BG1
CH3 40 F A T3N0M0 2 Na BG1
CH4 48 M A T2N0M0 3 P BG1 and BG5
CH5 53 M SF T3N0M0 2 P AC
CH6 77 M A T1N0M0 2 P Na
CH7 73 M A T3N0M0 2 P Na
CH8 38 F C T3N0M0 2 P BG1
CH9 80 M A T3N1M0 3 Na Na
CH10 29 F S T2N0M0 2 P BG1
CH11 51 F SF T3N0M0 2 P AC
CH12 44 M R Advanced adenoma Severe dysplasia AB BG1 and BG5
TR13 56 M C/R T3N0M0/T1N0M0 G3/G2 P BG2 and BG5
Note: CH6 ¼ 52557 and CH7 ¼ 61263 in Truninger et al. (2005).
MSI, microsatellite instability at BAT26 and dinucleotide repeats on 7p22; P, present; AB, absent; m, male; f, female; C, cecum; A, ascending; SF,
splenic ﬂexure; S, sigmoid colon; R, rectum; AC, revised Amsterdam Criteria; BG, revised Bethesda Guidelines; Na, not available.
aTNM and tumor grade classiﬁcation according to Sobin and Wittekind (2002).
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Sequence Pilot algorithm, version 3.3 (JSI Medi-
cal Systems, Kippenheim, Germany). A relative
probe signal of 1 (¼ 100%) in a sample DNA
reﬂects to two copies of target sequence of
PMS2- and PMS2CL-speciﬁc probes and four cop-
ies of target sequence of universal probes which
bind to both PMS2 and PMS2CL sequences.
Hence, relative probe signals of 0.5 (50%) and 1.5
(150%) of PMS2- and PMS2CL-speciﬁc probes
indicate one and three DNA copies, respectively,
of the respective target sequences. A reduction to
0.75 (75%) indicates a copy number change from
four to three copies of target sequence of univer-
sal probes.
cDNA Sequencing of PMS2 and
PMS2CLTranscripts
This approach was used to conﬁrm MLPA
ﬁndings of a PMS2 exon 8 deletion in patient
CH11 and those for patient TR13 showing a del-
eterious hybrid PMS2 allele containing a
PMS2CL-derived sequence in exons 11-15. In the
former case, we extracted RNA from the patient’s
freshly collected blood lymphocytes and reverse-
transcribed it using the High Capacity RNA-to-
cDNA kit (Applied Biosystems, Foster City, CA).
cDNA containing PMS2 exons 6–9 was PCR-
ampliﬁed with primers PMS2/11 (forward) and
PMS2/4 (reverse) (Supporting Information Table
S1). These primers were also used to sequence
the resulting RT-PCR product. In case TR13, we
extracted RNA from a short-term culture of the
patient’s lymphocytes, which had been treated
with puromycin before harvest (Etzler et al.,
2008) to prevent nonsense-mediated decay
(Andreutti-Zaugg et al., 1997). The entire coding
sequence of PMS2 was ampliﬁed in two partially
overlapping RT-PCR products, as previously
described (Etzler et al., 2008). The amplicons
were sequenced with internal primers (Support-
ing Information Table S1), directly and after
cloning into the pCR4-TOPO vector (Invitrogen,
Carlsbad, CA). In the latter case, 10 clones were
sequenced after ampliﬁcation of the plasmid
inserts by colony PCR performed under standard
conditions with Taq DNA polymerase (New
England Biolabs GmbH, Frankfurt am Main,
Germany) and M13 forward and reverse primers.
PMS2CL transcripts from the same patient were
RT-PCR-ampliﬁed and subsequently sequenced
as previously described (Ganster et al., 2010).
All sequence reactions were performed with
Big Dye Terminator chemistry V1.1 (Applied
Biosystems) on the Applied Biosystems 3130
Genetic Analyzer. Before sequencing, PCR prod-
ucts were treated with ExoSAP-IT (GE Health-
care, Vienna, Austria), and sequences were
analyzed with the Sequence Pilot algorithm Ver-
sion 3.3 (JSI Medical Systems, Kippenheim,
Germany).
Determination of the Extent of the Exon 8
Deletion at the gDNA Level
The exon 8-deleted allele from patient CH11
was ampliﬁed from gDNA with primers PMS2_7f
(forward) and PMS2/4 (reverse), which are
located in PMS2 intron 6 and exon 9, respectively
(Supporting Information Table S1). Phusion
High-Fidelity DNA polymerase (Finnzymes,
Espoo, Finland) was used in a reaction containing
3% DMSO under the PCR conditions recom-
mended by the manufacture. The resulting PCR
product (i.e., a single band presumably derived
from the deletion-containing allele) was
sequenced with forward primer PMS2/3 (Support-
ing Information Table S1) located within exon 7.
Genomic Array Analysis of the Deletion
Encompassing the Entire PMS2 Gene and
Flanking Sequences
The Affymetrix Genome-Wide Human SNP
6.0 array platform (Affymetrix, Santa Clara, CA)
TABLE 2. Coriell Cell Repository DNA Samples Identiﬁed as Valid References for Use with the P008-B1 PMS2 MLPA Kit
DNA numbera Catalog ID Description
NA07348 GM07348 CEPH/UTAH pedigree 1345
NA10842 GM10842 CEPH/UTAH pedigree 1423
NA07019 GM07019 CEPH/UTAH pedigree 1340
NA12853 GM12853 CEPH/UTAH pedigree 1400
NA17002 GM17002 Human variation panel – Northern European
NA17005 GM17005 Human variation panel – Northern European
NA17008 GM17008 Human variation panel – Northern European
NA17009 GM17009 Human variation panel – Northern European
aEach sample listed was MLPA-veriﬁed to contain two copies of PMS2-speciﬁc and two copies of PMS2CL-speciﬁc sequences. MLPA proﬁles of all
24 Coriell DNAs investigated in this study are available on request.
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was used according to the manufacturer’s instruc-
tions for genomic copy number proﬁling. Probe
allocation was based on the March 2006 human
reference sequence (NCBI Build 36.1). Raw
probe data ﬁles were processed within the R sta-
tistical software framework (http://www.R-project.
org) with additional packages from the aroma.
affymetrix project (http://aroma-project.org). Copy
numbers were estimated with the CRMAv2
method (Bengtsson et al., 2009), which includes
allelic cross-talk calibration, normalization for
probe sequence effects, and normalization for
PCR fragment-length effects. Copy numbers
were segmented using the Circular Binary Seg-
mentation method (Venkatraman and Olshen,
2007). Normalized probe and segmentation data
were visualized with custom software developed
for the Progenetix project (Baudis and Cleary,
2001).
Breakpoint Analysis of the Deleterious Hybrid
PMS2 Allele and Development of an Assay
for its Detection
The sequence exchange breakpoint responsible
for the deleterious hybrid PMS2 allele in case
TR13 was expected to lie in intron 10. There-
fore, we speciﬁcally ampliﬁed a 2,314-bp PCR
fragment from gDNA containing the deleterious
hybrid allele using a PMS2-speciﬁc primer
located in exon 10 (PMS2B_F) and a PMS2CL-
speciﬁc primer in exon 11 (PMS2CLc.1238CC_
R). The fragment was then sequenced with seven
internal sequencing primers (Supporting Informa-
tion Table S1).
We developed a simple PCR-based assay for
detecting the deleterious hybrid PMS2 allele. Pri-
mers ﬂanking the identiﬁed breakpoint were
designed to speciﬁcally amplify sequences from
the hybrid allele. These primers, that is, a PMS2-
speciﬁc forward primer (PMS2inIVS10_gen_1f)
and a PMS2CL-speciﬁc reverse primer (PMS2i-
nIVS10_psgen_1r), generate a 239-bp hybrid
allele-speciﬁc PCR product (Supporting Informa-
tion Table S1). They were used in a duplex PCR
reaction with primers that generate a 696-bp con-
trol PCR product (PMS2in14_1F and PMS2B_
Rnew) (Supporting Information Table S1).
NCBI Reference Sequences
NCBI reference sequences (RefSeqs) NG_
008466.1 and NM_000535.5 were used for the
human PMS2 gene and human PMS2 mRNA,
respectively. RefSeq NC_000007.13 was used for
the human PMS2CL pseudogene. The sequence
variants that discriminate between the PMS2 and
PMS2CL paralogs are those published by Hay-
ward et al. (2007); they are given as variants
with respect to the PMS2 RefSeq. All variants
are described in accordance with the Human
Genome Variation Society (http://www.hgvs.org/
mutnomen) guidelines, with the A of the ATG
start codon as position c.1.
RESULTS
Publicly Available Reference DNA Samples for
PMS2 MLPA Analysis
Because of the high prevalence of nondeleteri-
ous hybrid PMS2 and PMS2CL alleles, the distri-
bution of PMS2 and PMS2CL-speciﬁc sequences
downstream of exon 12 displays high interindivid-
ual variability (Hayward et al., 2007;Ganster
et al., 2010; van der Klift et al., 2010). Randomly
chosen reference samples of DNA are thus likely
to differ widely in terms of the distribution of
gene- and pseudogene-derived sequences in this
region. This is reﬂected by high standard devia-
tions for the reference DNA signals generated
with all the paralog-discriminating probes located
downstream of exon 12 (Supporting Information
Fig. S1). It is important to note that an unequal
distribution of gene-derived and pseudogene-
derived sequences in the reference DNA set will
reduce the accuracy of copy number assessments
at these loci in patient DNA samples. For this
reason, reference DNAs must harbor two PMS2-
speciﬁc copies and two PMS2CL-speciﬁc copies
of each sequence bound by paralog-discriminat-
ing probes for exons 11-15.
To obtain a set of reference samples that could
be used by all laboratories performing PMS2
MLPA, we evaluated 24 DNA samples from
EBV-immortalized lymphocytes, which can be
obtained from Coriell Cell Repositories. MLPA
ﬁndings for these candidates were compared with
those for ﬁve previously characterized DNA sam-
ples (Ganster et al., 2010) that met the criteria
listed above. Sixteen (67%) of the candidates
showed MLPA signals reﬂecting an unequal dis-
tribution of gene-derived and pseudogene-
derived sequences (Fig. 1). The other eight
(33%) met the prerequisites for suitable reference
samples (Table 2). Each subsequent MLPA
experiment was performed with a control set con-
sisting of ﬁve of these samples (randomly chosen
for each experiment).
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Alterations Identiﬁed by PMS2 MLPA Analysis of
gDNA from Patients with PMS2-Deﬁcient
Colorectal Tumors
As shown in Figure 1B, aberrant MLPA signals
indicating a deleterious PMS2 alteration were de-
tected in three (23%) of the 13 patients with PMS2-
deﬁcient colorectal tumors (Table 1). In Patient CH8,
the assay revealed loss of one PMS2-speciﬁc DNA
copy of exons 1-12 and the presence of two PMS2CL-
speciﬁc DNA copies in exons 11 and 12 (Fig. 1B;
Supporting Information Fig. S2). We found reduced
probe signals indicative for three (instead of four) cop-
ies of the sequences bound by the nonspeciﬁc probes
for exons 12, 13, 14, and 15. Paralog-speciﬁc probe
signals for the latter three exons disclosed that
the three copies were all PMS2-derived (Fig. 1B,
Supporting Information Fig. S2). This MLPA pattern
is most likely the result of a deletion encompassing
the entire PMS2 gene and the concomitant presence
of two hybrid PMS2CL alleles containing PMS2-
speciﬁc sequences in exons 13-15. The latter alleles,
together with the remaining nonhybrid, wild-type
PMS2 allele, would account for the three gene-spe-
ciﬁc signals in exons 13-15.
Genomic array analysis (Supporting Informa-
tion Fig. S3) conﬁrmed the presence of a large
(125 kb) deletion containing the entire PMS2
gene, three other genes (ANKRD61, AIMP2
[JTV1], and EIF2AK1), and a portion of the cod-
ing region of RSPH10B. The distal breakpoint of
the deletion was located downstream to PMS2, in
the center of the telomeric duplicon, between
probes CN_1240840 and CN_1240842 [at nucleo-
tides 5,970,140 and 5,970,432 (NCBI build 36.1/
hg18), corresponding to between 6,003,614
and 6,003,906 in GRCh37/hg19]. The proximal
breakpoint lay within the interval of nucleotides
6,095,502–6,097,302; probes CN_1240873 and
CN_1240874 (corresponding to 6,121,772–
6,137,980 in hg19, respectively) which is located
within the 0.7-Mb sequence separating the telo-
meric and centromeric duplicon. Interestingly,
this breakpoint falls within the range reported for
a deletional CNV that has been observed in a
number of studies (e.g., Kidd et al., 2008).
In patient CH11, MLPA showed loss of one
DNA copy at the site hybridized by the exon 8
probe (Fig. 1B). Sequencing of exon 8 from
Figure 1. PMS2 MLPA results for reference DNA candidates and
DNA samples from patients with colorectal tumors displaying isolated
PMS2 expression loss. (A) Schematic showing ligation sites for the
probes in the redesigned (P008-B1) PMS2 MLPA kit. Paralog-discrimi-
nating ligation sites are shown in boldface. Rectangles: exons 11–15 of
PMS2 (and PMS2CL); lines: introns. (B) MLPA results (given as copy
numbers of the DNA sequences bound by the MLPA probes) for 24
reference DNA sample candidates (obtained from Coriell Cell Reposi-
tories) and 13 patient DNA samples. Results are grouped for exons 1–
7 (E1-E7) and 9 and 10 (E9 and E10) and reported individually for
exons 8 (E8) and exons 11 (E11) to 15 (E15), the latter being shared
by the paralogs. The paralog-discriminating sequence variants at the liga-
tion sites of the probes in exons 11–15 are color-coded: green, PMS2-
speciﬁc probes; red, PMS2CL-speciﬁc probes; black, nonspeciﬁc probes.
Numbers in cells (0–4): copies of exon sequences in sample. Paired
gray cells: uneven distribution of PMS2- and PMS2CL-speciﬁc signals in
samples with a total of four copies, which reﬂects the presence of non-
deleterious hybrid alleles (PMS2 or PMS2CL). Orange cells: aberrant
MLPA results in patient CH8 (reﬂecting deletion of all PMS2 exons);
patient CH11 (exon 8 deletion); and patient TR13 (who had a deleteri-
ous PMS2 hybrid allele; see text for details). [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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gDNA excluded sequence alterations at this site,
whereas sequencing of an RT-PCR product com-
prising PMS2 exons 6–9 revealed heterozygous
loss of exon 8 in the patient’s transcripts (data
not shown). Collectively, these results conﬁrmed
the presence of a genomic deletion involving
PMS2 exon 8.
To characterize better this deletion, we ampli-
ﬁed patient gDNA using a forward primer
(PMS2_7f) located in intron 6 and a reverse
primer (PMS2/4) in exon 9. The amplicon pro-
duced a single band in agarose gel electrophoresis
and was 3,400 shorter than the expected prod-
uct of wild-type allele ampliﬁcation (2,200 vs.
5,597 bp), which indicates that only the deletion-
carrying allele is ampliﬁed under the PCR condi-
tions we used. Sequencing of this amplicon with
an internal primer showed that the breakpoints of
this 3,351-bp deletion (i.e., c.803þ384_904-
1533del) were located within two identically ori-
ented AluSb elements in introns 7 and 8.
MLPA results for the third patient (TR13)
revealed one gene-speciﬁc and three pseudogene-
speciﬁc DNA copies at all probe sites in exons
11, 12, and 15 (Fig. 1B). In exons 13 and 14, the
patient harbored two PMS2- and PMS2CL-speciﬁc
copies (Figs. 1B and 2A). These ﬁndings are in-
dicative of a hybrid PMS2 allele containing a
PMS2CL-derived sequence, which starts at the
beginning of exon 11 (position c.1360_1361,
where the ﬁrst PMS2-speciﬁc MLPA probe in
exon 11 is located; see Fig. 1A) and extends at
least 1,099 bp downstream from exon 12 (speciﬁ-
cally, to position c.2174þ1097_2174þ1099, where
the gene-speciﬁc and pseudogene-speciﬁc intron
12 probes are located; see Fig. 1A). Compared
with its PMS2 paralog, the PMS2CL exon 11
sequence contains two frame-shift variations
(c.1730dupA and c.1863_1864delTA). As each of
these variations produces a premature stop codon
when introduced into PMS2, the hybrid allele can
be classiﬁed as deleterious.
We suspected that the PMS2CL-derived
sequence in this hybrid allele extended even far-
ther downstream, into or past exon 15, and that
the equal distribution of gene- and pseudogene-
speciﬁc sequences (2:2) in exons 13 and 14 might
reﬂect the presence of a hybrid PMS2CL allele
containing PMS2-speciﬁc sequences in these
exons. To conﬁrm this hypothesis, we sequenced
PMS2 transcripts from the patient that had been
ampliﬁed as described by Etzler et al. (2008)
using a forward primer located in exon 10 and a
reverse primer downstream of the termination
codon. Direct sequencing of the RT-PCR prod-
ucts (Supporting Information Fig. S4) showed
Figure 2. MLPA results showing the deleterious hybrid PMS2 allele in
patient TR13. (A) Bars in upper and lower histograms represent MLPA
probes. Probe labels appear under the lower histogram. Probes for
exons (E) 11–15 are designated gene-speciﬁc (G), pseudogene-speciﬁc
(P), or nonspeciﬁc (GþP). Upper histogram: Lavender bars indicate
mean probe signals with standard deviations for ﬁve of the selected refer-
ence DNAs reported in Table 2; green bars: probe signals for patient
DNA. Numbers below the green bars indicate the amplicon size (in nts)
of the corresponding MLPA probe. Lower histogram: the bar for each
probe represents the probe signal for patient DNA as a percentage of
the mean signal for the reference DNAs. Lavender bars represent per-
centages ranging from 75 to 125% (red dotted lines); larger discrepancies
between patient and reference samples are represented by violet bars.
(B) Number of DNA copies at sites hybridized by probes for exons 11–
15 and deduced patient genotypes. Green ‘‘g’’: PMS2-speciﬁc sequence;
red ‘‘p’’: PMS2CL-speciﬁc sequence; D: absent in PMS2CL (exon 10) (see
text for explanation of these results). [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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heterozygosity for all known PMS2CL-speciﬁc
sequence variants in exons 11–14 and homozygos-
ity for the PMS2CL-speciﬁc variant c.*92dupA in
exon 15. When individual RT-PCR products
were sequenced after cloning, the results con-
ﬁrmed the presence of the deduced deleterious
PMS2 hybrid allele (with sequences in exons 11–
15 that were all PMS2CL-derived). They also
showed that the other PMS2 allele was a nonde-
leterious hybrid containing the pseudogene-
derived variant c.*92dupA. Moreover, cDNA
sequencing of PMS2CL transcripts conﬁrmed the
presence of a nonhybrid allele, together with the
expected hybrid PMS2CL allele containing
PMS2-speciﬁc sequences in exons 13–15 (data
not shown). This complex genotype (Fig. 2B)
explains the gene:pseudogene copy number ratios
observed in exons 11, 12, and 15 (1:3) and in
exons 13 and 14 (2:2).
Characterization of the Breakpoint of Sequence
Exchange Between PMS2 and PMS2CL Leading to
the Deleterious PMS2 Hybrid Allele
Recombination with crossover between the
paralogous sequences is the most likely mecha-
nism underlying the formation of the deleterious
hybrid PMS2 allele (Fig. 3A). Because the recom-
bination breakpoint was expected to lie 50 of
exon 11, in intron 10, we ampliﬁed a 2314-bp
Figure 3. Breakpoint analysis and allele-speciﬁc PCR detection of
the deleterious hybrid PMS2 allele in patient TR13. (A) Schematic
showing sequence exchange between PMS2 and PMS2CL due to intra-
chromosomal recombination with crossover. Upper ﬁgure: Normal
locations on 7p22 of gene (green); pseudogene (red); and 100-kb
duplicons (gray hatching). Arrowheads indicate direction of transcrip-
tion. The 0.7-Mb interduplicon sequence is shown as an arrow. Mid-
dle ﬁgure: intrachromosomal recombination with crossover produces
a hybrid PMS2CL allele (in the telomeric duplicon) containing a PMS2-
derived sequence and a hybrid PMS2 allele (partially embedded in the
centromeric duplicon) that contains a PMS2CL-derived sequence 30 of
the recombination breakpoint (intron 10; IVS10). The interduplicon
sequence has also been inverted. Lower ﬁgure: zoom showing the
hybrid PMS2 allele with PMS2-derived (green) and PMS2CL-derived
(red) sequences. (B) Zoom (not to scale) showing the breakpoint
region of the deleterious hybrid PMS2 allele. The heavy black line
between exons 10 and 11 (rectangles) represents intron 10. Vertical
bars represent PMS2-derived (green) and PMS2CL-derived (red)
sequence variants. Horizontal arrows represent allele-speciﬁc primers
spanning the breakpoint (gene-speciﬁc in green, pseudogene-speciﬁc
in red). The resulting allele-speciﬁc PCR products (2,314 and 239 bp
long) are indicated (light gray brackets), and the breakpoint region is
enclosed in a dotted rectangle (light gray). (C) Results of the duplex
PCR assay for the deleterious hybrid PMS2 allele in patient TR13 (P)
and two of the 150 normal controls (C) tested. The 696-bp control
PCR product was present in the patient and all 150 controls; the
239-bp PCR product speciﬁc for the deleterious hybrid PMS2 was
present only in the patient sample. M: 100 bp DNA ladder; W: nega-
tive (water) control. [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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fragment containing this intron 10 speciﬁcally
from the deleterious hybrid allele. For this pur-
pose, we used a gene-speciﬁc forward primer
located in exon 10 and a pseudogene-speciﬁc
reverse primer in exon 11. As shown in Figure
3B, sequencing of the amplicon revealed PMS2-
speciﬁc single-nucleotide variants at all paralog-
discriminating sites 50 of nucleotide c.1145-942
(inclusive) and PMS2CL-speciﬁc single-nucleotide
variants 30 of nucleotide c.1145-790 (inclusive).
These two nucleotides delimit the 153-bp break-
point region, which includes three additional
paralog-discriminating, single-nucleotide variants:
one derived from PMS2CL (the adenine at posi-
tion c.1145-921) and two from PMS2 (the guanine
and inserted cytosine at positions c.1145-886 and
c.1145-880_1145-879, respectively; Fig. 3B). This
pattern of gene- and pseudogene-speciﬁc variants
within the breakpoint region reﬂects the type of
double Holliday junction resolution that leads to
strand crossover in the recombination-initiated,
double-strand break repair process (as well-illus-
trated in Fig. 1 of Chen et al., 2007), thereby
conﬁrming that recombination with crossover is
the mechanism that generated this deleterious
hybrid PMS2 allele.
Because PMS2 and PMS2CL are oppositely ori-
ented, interparalog crossover is more likely to
occur intrachromosomally. This process would
generate two reciprocal hybrids, each containing
paralog-derived sequences (Fig. 3A). However, in
the presence of a reciprocal hybrid PMS2CL al-
lele, the deleterious hybrid PMS2 allele found in
patient TR13 would have escaped detection by
MLPA because of the equal numbers of gene-
speciﬁc and pseudogene-speciﬁc sequences (2:2)
in exons 11 and 12. PMS2-speciﬁc cDNA
sequencing (Etzler et al., 2008; van der Klift
et al., 2010) as well as approaches based on
PMS2-speciﬁc long-range PCR (Vaughn et al.,
2010) would detect the deleterious hybrid allele
also in this conformation. However, high quality
RNA and gDNA is needed for these assays. As
such material is frequently not available of retro-
spective patient’s cohorts, we developed a simple
PCR assay that identiﬁes this deleterious hybrid
allele even when it is accompanied by its recipro-
cal hybrid PMS2CL allele. This assay can be used
as screening tool in large retrospective cohorts. It
is based on the use of primers that speciﬁcally
amplify a 239-bp breakpoint-including fragment
from the deleterious PMS2 hybrid allele (Fig.
3B). This reaction is duplexed with a control
PCR that generates a 696-bp fragment using non-
speciﬁc primers located in exon 15 (Ganster
et al., 2010). After verifying its speciﬁcity in the
analysis of DNA samples from 150 control indi-
viduals (Ganster et al., 2010), all of which were
negative for the 239-bp long PCR product (Fig.
3C), we used the new assay to retest the 10
patients in our cohort whose suspected PMS2
mutation had not been veriﬁed. Negative ﬁndings
in all 10 cases exclude the possibility that a recip-
rocal PMS2CL hybrid allele is masking the pres-
ence in these individuals of the deleterious
hybrid PMS2 allele found in patient TR13.
DISCUSSION
The high prevalence of clinically irrelevant
PMS2 and PMS2CL hybrid alleles (found in
70% in the Caucasian population; van der Klift
et al., 2010) has seriously hindered MLPA-based
detection of copy number changes involving
PMS2 exons 13–15. Our ﬁndings conﬁrm that
PMS2 MLPA analysis can be substantially
improved by the use of MRC Holland’s recently
redesigned PMS2 MLPA kit (P008-B1), together
with selected reference DNA samples known to
carry two PMS2-derived and two PMS2CL-
derived sequences in this region (Vaughn et al.,
2011). The eight reference samples we veriﬁed
for use in this study can be adopted as controls
for this assay in any diagnostic laboratory. They
are publicly available (from Coriell Cell Reposito-
ries), and because they are derived from EBV-
immortalized lymphocyte cell lines, their avail-
ability is long-term. Routine use of these refer-
ence DNAs can facilitate standardization of
MLPA analysis.
With this improved MLPA approach, we ana-
lyzed germline DNA from 13 patients with colo-
rectal tumors characterized by isolated PMS2
expression loss. The assay identiﬁed deleterious
germline alterations involving the PMS2 locus in
3 (27%) of the 11 cases in which MLPA was the
ﬁrst-line method of mutation analysis (23% of the
entire cohort). These ﬁgures are consistent with
previous MLPA ﬁndings in colon cancer series
similar to our own. Deleterious PMS2 copy num-
ber alterations were found in 11 (17%) of 65
patients tested in a US laboratory (Vaughn et al.,
2010, 2011) whereas a Dutch group reports that
up to 33% (15/45) of the analyzed patients carry
germline PMS2 mutations that should be detecta-
ble with the P008-B1 PMS2 MLPA kit (van der
Klift et al., 2010; van der Klift and Tops, personal
communications).
A DELETERIOUS PMS2-PMS2CL HYBRID ALLELE 9
Genes, Chromosomes & Cancer DOI 10.1002/gcc
To gain new insight into the mechanisms that
generate PMS2 mutations, we characterized the
alterations found in our cohort in greater detail.
The 3,351-bp deletion that included PMS2 exon
8 (Patient CH11) was probably caused by recom-
bination of two identically oriented AluSb ele-
ments in introns 7 and 8. Together with the two
other previously described Alu recombination-
mediated deletions, our ﬁnding strengthens the
view that the frequency of deletions involving
PMS2 is related in part to the high density of Alu
elements within the genomic sequence of this
gene (van der Klift et al., 2005).
The deletion found in patient CH8 was much
larger (125 kb). It included the entire PMS2
gene and at least three other genes as well. Two
of these genes (EIF2AK1 and AIMP2) have tu-
mor-suppressing functions. EIF2AK1 suppresses
protein synthesis during various conditions of
stress by blocking the initiation of translation.
This inhibition has been shown to annul the pro-
liferative capacity of differentiating erythroid cells
(Crosby et al., 2000), and similar effects might
occur in colorectal tissues, where EIF2AK1 is
highly expressed (our data, not shown).
As for the second gene, AIMP2, its promoter
region lies head-to-head with and partially over-
laps that of PMS2 (NCBI RefSeq NG_008466.1;
Nicolaides et al., 1995). The expression of this
gene in colorectal tissues is even more abundant
than that of PMS2 (our data, not shown): it enco-
des a component of the amino-acyl-tRNA synthe-
tase complex (Kim et al., 2002), which exerts
both antiproliferative and proapoptotic activities
in diverse cell types. On TGF-b stimulation,
AIMP2 mediates ubiquitination and degradation
of FUBP1, a transcriptional activator of the proto-
oncogene MYC (Kim et al., 2003). Furthermore,
DNA damage due to genotoxic stress is followed
by phosphorylation of AIMP2, which then pro-
motes apoptosis by protecting TP53 from
MDM2-mediated ubiquitination and degradation
(Han et al., 2008). AIMP2 also promotes TNF-a-
dependent apoptosis via ubiquitination-mediated
degradation of TRAF2 (Choi et al., 2009a). Most
importantly, reduced AIMP2 expression level in
Aimp2 heterozygous mice is associated with
increased susceptibility to cancer in the colon
and other tissues as well (Choi et al., 2009b).
AIMP2 is probably involved in all PMS2 deletions
affecting exon 1 and sequences 30 to this exon.
Thus far, PMS2 deletions of this type have been
reported in eight further families (Hendriks et al.,
2006; Overbeek et al., 2007; Senter et al., 2008;
Vaughn et al., 2010; Herkert et al., 2011). It may
be interesting to investigate in future studies
whether inactivation of the AIMP2 gene contrib-
utes as a modiﬁer to the expression of Lynch
syndrome.
The deleterious alteration identiﬁed in patient
TR13 was a hybrid PMS2 allele generated by
recombination with crossover, one possible reso-
lution of a double Holliday junction. The recom-
bination breakpoint was located in PMS2 intron
10, just 578 bp 30 of a 2.7-kb sequence that is
present in PMS2 and deleted in PMS2CL. This
major dissimilarity between gene and pseudogene
(Fig. 3B) impedes alignment of the paralogous
sequences at the inner ends of the duplicons;
consequently, the rate of interparalog recombina-
tion should be very low in this region (Fig. 3A)
(Hayward et al., 2007). Indeed, of all the break-
points reported thus far to cause sequence
exchange between the human PMS2 and
PMS2CL genes, the one that generated the dele-
terious hybrid PMS2 allele found in patient TR13
is the most proximal (i.e., closest to the inner
ends of the duplicons). The next closest – located
approximately 1,500 bp downstream from the
breakpoint we describe – also generated a delete-
rious hybrid PMS2 allele associated with Lynch
syndrome (Auclair et al., 2007). It contained two
adjacent PMS2CL-speciﬁc sequence variants
(c.1730dupA and c.1732C>T) in exon 11, which
were probably inserted by the nonreciprocal
mechanism of gene conversion, another possible
result of the resolution of a double Holliday-junc-
tion (Auclair et al., 2007). This hybrid allele and
the one found in patient TR13 are the only dele-
terious PMS2 alterations reported thus far that
have been attributed to sequence exchange
between PMS2 and PMS2CL. This conﬁrms pre-
vious observations that interparalog recombina-
tion events located 50 to intron 12 are much less
common than those occurring downstream of
exon 12 (Hayward et al., 2007; Ganster et al.,
2010; van der Klift et al., 2010).
We recently characterized a nondeleterious
hybrid PMS2 allele produced by recombination
with crossover with a breakpoint in intron 12
(Ganster et al., 2010). As discussed above and
shown for this hybrid allele, intrachromosomal
recombination resulting in crossover of paralog
sequences is expected to produce reciprocal
hybrid PMS2 and PMS2CL alleles (Fig. 3A).
But, the expected hybrid PMS2CL allele was
not found in patient TR13 or any of his relatives.
Indeed, in this family, the deleterious hybrid
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PMS2 allele and the nonhybrid PMS2CL allele
segregate together, as shown by MLPA analysis
of the proband’s mother, one of his maternal
cousins, and the latter’s son (all mutation carriers)
and four unaffected individuals, including the
proband’s daughter and brother (data not shown).
These two alleles are thus located on the same
chromosome. This ﬁnding is compatible with two
possible mechanisms of hybrid allele formation
(Fig. 4).
In the ﬁrst hypothesis (Fig. 4A), an initial intra-
chromosomal recombination with crossover event
generated the deleterious hybrid PMS2 allele.
This allele was later separated from its reciprocal
hybrid PMS2CL allele by an interchromosomal
recombination event with a chromosome carrying
a nonhybrid PMS2 allele and a nonhybrid
PMS2CL allele separated by a 0.7-Mb sequence
whose orientation was inverted with respect to
the normal conformation – a situation observed in
at least 5% of all Caucasians (Feuk et al., 2005).
If this mechanism generated the deleterious
PMS2 hybrid allele, the interchromosomal recom-
bination event must have taken place at least two
generations before that of the proband and sev-
eral generations after the intrachromosomal
recombination event (more details below). Alter-
natively, the two steps might have been com-
pleted simultaneously, in a single, complex
recombination event occurring at least one gener-
ation before that of the proband’s mother.
In the second hypothesis (Fig. 4B), there is
only one step: an interchromosomal recombina-
tion event between two chromosomes with PMS2
Figure 4. Possible mechanisms leading to the conﬁguration found
in patient TR13: a deleterious hybrid PMS2 allele with no reciprocal
hybrid PMS2CL allele. The normal conﬁguration depicted at the tops
of panels A and B is that shown in Figure 3A (see legend of Fig. 3 for
meaning of colors and symbols). (A) First hypothesis: Event I. Intra-
chromosomal recombination with crossover generates chromosome
A (Chr.A) containing both the deleterious hybrid PMS2 allele and a
reciprocal hybrid PMS2CL allele. The recombination breakpoint is
located in intron 10 (IVS10). Event II (occurring simultaneously with
or after Event I). Interchromosomal recombination with crossover
(the breakpoint is in the 0.7-Mb interduplicon sequence) between
Chr.A and Chr.B (characterized by a common inverted conﬁguration
that is nondeleterious) gives rise to the conﬁguration observed in
patient TR13 (Chr.C): the deleterious hybrid PMS2 allele and a nor-
mal PMS2CL allele. (B) Second hypothesis: interchromosomal recom-
bination event between Chr.B (as described in panel A) and a
chromosome with the normal conﬁguration (Chr.E). With the recom-
bination breakpoint located within intron 10, this sequence exchange
generates the deleterious PMS2 hybrid allele found in patient TR13
(Chr.C). [Color ﬁgure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
A DELETERIOUS PMS2-PMS2CL HYBRID ALLELE 11
Genes, Chromosomes & Cancer DOI 10.1002/gcc
and PMS2CL in opposite duplicons and separated
by oppositely oriented 0.7-Mb sequences.
These considerations may have also diagnostic
implications. If the mechanism illustrated in Fig-
ure 4B is responsible for its formation, the delete-
rious hybrid PMS2 allele found in patient TR13
might have arisen very recently. The same is true
if it was generated as shown in Figure 4A with si-
multaneous intrachromosomal and interchromoso-
mal recombination events. In either case, the
deleterious hybrid allele would be very rare in
our proband’s population. In contrast, if the intra-
chromosomal and interchromosomal events
depicted in Figure 4A occurred successively
rather than simultaneously, they were probably
separated by an interval of more than 130 genera-
tions (assuming an average recombination rate of
1.1 cM Mb1 for the 0.7-Mb sequence between
the duplicons; Kong et al., 2002). And during this
interval, the reciprocal hybrid alleles would have
spread through a considerable portion of the pop-
ulation, in tandem. This latter mutational conﬁg-
uration, however, would escape detection by
MLPA analysis (see ‘‘Results’’ Section), but, it
could be identiﬁed by PMS2-speciﬁc cDNA
sequencing or by the deleterious hybrid allele-
speciﬁc multiplex assay we developed (Figs. 3B
and 3C).
Future studies using one or both of these
assays to test patients with colon cancers charac-
terized by isolated loss of PMS2 expression and
with negative results at ﬁrst-line mutation analy-
sis will shed light on the true frequency of this
deleterious hybrid allele and the possibility that
it represents a founder mutation in the popula-
tion inhabiting the eastern Alpine valleys of Italy
(where patient TR13 comes from). In turn, iden-
tiﬁcation of this allele in other patients could pro-
vide us with additional information on the
recombination mechanism that might have gener-
ated it.
In conclusion, using the P008-B1 PMS2 MLPA
kit and a set of selected reference DNAs that are
universally available, we identiﬁed deleterious
PMS2 alterations in 23% of our PMS2-deﬁcient
colorectal cancer patients (27% of those under-
going ﬁrst-line testing). The alterations found
included two deletions (conﬁrming the high fre-
quency of this type of alteration) and a deleteri-
ous hybrid PMS2 allele, which is particularly
interesting since almost all PMS2-PMS2CL
hybrids described thus far have been nondeleteri-
ous. These ﬁndings suggest that MLPA should
be considered a possible ﬁrst-line method for
PMS2 mutation analysis, especially when high-
quality RNA is not available for direct cDNA
sequencing.
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